UNSPSC 51282613: Cefozopran hydrochloride

This classification denotes a cephalosporin antibiotic with the molecular formula C19H17N9O5S2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 060I5C0GRC. European Medicines Agency schedules cefozopran hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13278MIG. The term cefozopran hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule cefozopran hydrochloride under HS 29419000 and SITC 54139.

As of Q4 2014, CEFOZOPRAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cefozopran hydrochloride bears US NLM identifiers UMLS ID C0141689 and NCI Concept Code C92168. SMILES: CO/N=C(/C1NC(SN1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4CCN5C4CCCN5)C(=O)[O-].CL.

UNSPSC 51282613 Cefozopran hydrochloride is a Commodity code designating a single injectable antibiotic product, yet the recent state and local opportunities tagged to it show no procurement activity for cefozopran itself. Instead, the tagged records document purchases of unrelated pharmaceutical products — doxycycline, ciprofloxacin, naloxone, and drug deactivation systems — suggesting a mismatch between the code's nominal scope and the work actually being solicited under it in state and local procurement systems. State and local buyers posting pharmaceutical procurement opportunities do not appear to be using this code consistently to flag antibiotic acquisitions; the opportunities show instead that state health departments and county health systems are using cooperative purchasing vehicles and direct competitive bids to source broad classes of pharmaceutical inventory, emergency response supplies, and public health commodities without precision coding at the individual active-ingredient level.

The source shows no recent open solicitations for cefozopran hydrochloride. One completed award — Illinois Department of Public Health's $2,999,999.11 piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 — addressed doxycycline and ciprofloxacin, while a Seminole County, Florida IFB posted in June 2026 sought naloxone and drug deactivation systems with a July 26, 2026 response deadline. Neither opportunity reflects the cefozopran category's stated scope. The code's inactivity and the consistent divergence between its nominal product and tagged opportunities suggest limited recent state and local demand under this code designation, or systematic tagging errors in the posting systems. Business development professionals evaluating this code should verify whether state and local buyers are consolidating antibiotic procurement under broader pharmaceutical family or class codes rather than individual commodity codes, or whether cefozopran acquisitions remain too specialized or low-volume to trigger routine competitive posting.